LoginSignup
Crispr Therapeut logo

Crispr Therapeut Stock

StockStock
ISIN: CH0334081137
Ticker: CRSP
CH0334081137
CRSP

Price

Frequently asked questions

What is Crispr Therapeut's market capitalization?

The market capitalization of Crispr Therapeut is $4.68B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Crispr Therapeut?

Crispr Therapeut's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$2.801. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Crispr Therapeut's stock?

Currently, 28 analysts cover Crispr Therapeut's stock, with a consensus target price of $84.29. Analyst ratings provide insights into the stock's expected performance.

What is Crispr Therapeut's revenue over the trailing twelve months?

Over the trailing twelve months, Crispr Therapeut reported a revenue of $202.83M.

What is the EBITDA for Crispr Therapeut?

Crispr Therapeut's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$313.02M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Crispr Therapeut?

Crispr Therapeut has a free cash flow of -$191.20M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Crispr Therapeut's stock?

The 5-year beta for Crispr Therapeut is 1.64. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Crispr Therapeut have, and what sector and industry does it belong to?

Crispr Therapeut employs approximately 407 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Crispr Therapeut's shares?

The free float of Crispr Therapeut is 83.87M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $4.68B

5Y beta

 1.64

EPS (TTM)

 -$2.801

Free Float

 83.87M

Revenue (TTM)

 $202.83M

EBITDA (TTM)

 -$313.02M

Free Cashflow (TTM)

 -$191.20M

Pricing

52W span
$43.42$91.10

Analyst Ratings

The price target is $84.29 and the stock is covered by 28 analysts.

Buy

13

Hold

11

Sell

4

Information

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

407

Biotechnology & Drugs

Health Care

Identifier

ISIN

CH0334081137

Primary Ticker

CRSP

Knockouts

Join the conversation
Sign upLogin